BCRT and Pluristem successful in treatment of muscle injuries


Research of the BCRT sheds light on promising cell treatment for muscle injuries

The Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charité - University of Medicine in Berlin, and Pluristem Therapeutics, Inc. announced the results of a pre-clinical study demonstrating that the local administration of PLX cells (Pluristem's PLacental eXpanded) following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This study suggests that Pluristem’s PLX cells have the potential to treat both accidental and intentionally induced muscle injuries.

During the study, either immediately or seven days after an injury to the soleus muscle, PLX cells or saline were injected into the traumatized muscles. Four weeks after administration, the regenerative capacity of the soleus muscle was measured bilaterally by stimulating the sciatic nerve. PLX cell administration resulted in a significant improvement in the recovery of function of the involved muscles.

“This is a landmark study because it is the first to show significant improvement of muscle injuries through the use of placental derived allogenic therapies,” said Prof. Dr. Georg N. Duda, head of the Julius Wolff Institute, co-head of the BCRT and principal investigator for the study. “The study demonstrates the great potential that Pluristem’s PLX cells hold for treating such injuries and we look forward to continuing to research this application and investigate its positive effects even further.”

Prof. Dr. Carsten Perka, head of orthopedics at the Center for Musculoskeletal Surgery at the Charité, emphasized the clinical need for this study: “A major problem for surgeons, especially in endoprosthetics, is muscular deficiencies, in particular muscular atrophy. Therefore, the approach of using PLX cells as adjuvant therapy to an orthopedic surgery is a unique opportunity to improve the healing outcome of patients.”

Based on the pre-clinical studies, Pluristem has initiated discussions with the German competent authority, for a clinical development plan in which PLX cells will be used as an adjuvant therapy for the recovery of muscle function following hip replacement surgery. "We are very encouraged by the findings of the Berlin-Brandenburg Center for Regenerative Therapies and look forward to moving ahead with the next stage of clinical research.” said Zami Aberman, Chairman, President and CEO of Pluristem.








<- Back to: News & Events